A single endoscopic duodenal ablation procedure maintained approximately 84% of GLP-1-induced weight loss at one year in selected patients, compared to 46% in sham-treated controls. This addresses a significant clinical gap: weight regain after GLP-1 discontinuation, which is common and well-documented.
Key Points
- Revita procedure maintained 84% of GLP-1 weight loss vs 46% sham at one year
- Results from optimized subgroup; pivotal trial data expected early Q4 2026
- No serious adverse events or new treatment-related harms through 12 months
Longevity Analysis
The ability to sustain metabolic benefit after pharmacotherapy withdrawal has direct implications for long-term cardiometabolic health and structured weight maintenance. Weight regain after GLP-1 cessation reflects the body's strong physiological drive to restore prior setpoint—a signal that requires addressing, not merely suppressing with continued medication. A procedure that can lock in metabolic advantage without ongoing drug exposure offers a different pathway to durability. The mechanism appears to involve altered duodenal signaling that sustains satiety and metabolic adaptation. Long-term relevance depends on whether the effect persists beyond one year and whether it generalizes across diverse patient populations and initial GLP-1 responses, which the pivotal cohort will determine.
Original published by Longevity.Technology, by Kyle Umipig.